Surveillance of primary sclerosing cholangitis – a comparison of scheduled or on-demand ERCP with annual MRI surveillance: a multicenter study

Abstract

Background

Primary sclerosing cholangitis (PSC) is associated with a high risk of hepatobiliary malignancy, especially cholangiocarcinoma (CCA). There are no good tumor markers to screen for CCA, and current recommendations for PSC monitoring are mainly based on expert opinions. The optimal strategy to assess disease progression and screen for CCA – the main cause of death of PSC patients – remains unclear. We aimed to compare three different surveillance strategies and their effect on patient outcomes.

Methods

Data from three distinct PSC cohorts with different surveillance strategies – scheduled endoscopic retrograde cholangiopancreatography (ERCP), annual magnetic resonance imaging/cholangiopancreatography (MRI/MRCP) surveillance, and on-demand ERCP according to ESGE/EASL guidelines – was collected. Patients with PSC diagnosed in 1990 or later were included and the last day of follow-up was 31 December 2023. The composite end point consisted of hepatobiliary malignancy, liver transplantation, or liver-related death.

Results

1629 PSC patients were included, with a median follow-up of 8–11 years. The cumulative incidence of the composite end point was lowest in the group undergoing scheduled ERCP (14.1%, 95%CI 12.0%–16.4%) and highest in the on-demand ERCP cohort (35.0%, 95%CI 28.4%–42.0%). Although the cumulative incidence of CCA was lower in the scheduled ERCP group than in the other groups, it did not differ statistically significantly from the MRI/MRCP surveillance group. No differences were seen in liver-related deaths between the surveillance strategies.

Conclusions

In this study comparing scheduled ERCP, annual MRI/MRCP surveillance, and on-demand ERCP, the strategy based on scheduled ERCP using individual risk stratification is associated with better overall prognosis and outcome.

Publication History

Received: 30 August 2024

Accepted after revision: 13 December 2024

Article published online:
28 January 2025

• References

• 1 Ponsioen CY, Assis DN, Boberg KM. et al. Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study group consensus process. Gastroenterology 2021; 161: 1764-1775
• 2 Bergquist A, Ekbom A, Olsson R. et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327
• 3 Manninen P, Karvonen AL, Laukkarinen J. et al. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 423-428
• 4 Boonstra K, Weersma RK, van Erpecum KJ. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055
• 5 Barner-Rasmussen N, Pukkala E, Jussila A. et al. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol 2020; 55: 74-81
• 6 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25: 659-671
• 7 Zenouzi R, Weismüller TJ, Hübener P. et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1733-1738
• 8 Karlsen TH, Folseraas T, Thorburn D. et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol 2017; 67: 1298-1323
• 9 EASL. Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022; 77: 761-806
• 10 Villard C, Friis-Liby I, Rorsman F. et al. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol 2023; 78: 604-613
• 11 Bergquist A, Weismüller TJ, Levy C. et al. Impact on follow-up strategies in patients with primary sclerosing cholangitis. Liver Int 2023; 43: 127-138
• 12 Boyd S, Tenca A, Jokelainen K. et al. Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. Endoscopy 2016; 48: 432-439
• 13 Stiehl A, Rudolph G, Klöters-Plachky PC. et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36: 151-156
• 14 Boyd S, Mustamäki T, Sjöblom N. et al. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study. Hepatol Commun 2024; 8: e0415
• 15 Barner-Rasmussen N, Sjöblom N, Arola J. et al. The role of serology, liver function tests and imaging in screening of primary sclerosing cholangitis: the HelPSCreen score. Scand J Gastroenterol 2023; 58: 1491-1498
• 16 van Munster KN, Mol B, Goet JC. et al. Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study. Liver Int 2023; 43: 639-648
• 17 Ali AH, Tabibian JH, Nasser-Ghodsi N. et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology 2018; 67: 2338-2351
• 18 Trivedi PJ, Crothers H, Mytton J. et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology 2020; 159: 915-928
• 19 Weismüller T, Trivedi PJ, Bergquist A. et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152: 1975-1984
• 20 Bowlus CL, Arrivé L, Bergquist A. et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2023; 77: 659-702
• 21 Chapman MH, Thorburn D, Hirschfield GM. et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019; 68: 1356-1378
• 22 Tan N, Ngu N, Worland T. et al. Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis. Hepatol Commun 2024; 8: e0442
• 23 Tenca A, Mustonen H, Lind K. et al. The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. Liver Int 2018; 38: 2329-2339
• 24 Rupp C, Hippchen T, Bruckner T. et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019; 68: 2170-2178
• 25 Koskensalo V, Aronen P, Färkkilä M. et al. Use of thiopurines is not a risk factor for post- ERCP pancreatitis in patients with primary sclerosing cholangitis. Dig Liver Dis 2021; 53: 1020-1027